Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AF-219 effect on cough reflex sensitivity in healthy volunteers and chronic cough patients
2015-000464-34Phase 2Completed
- Sponsor
- Afferent Pharmaceuticals, Inc.
- Start
- Mar 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of gefapixant in chronic cough (2 arms), sponsored by Afferent Pharmaceuticals, Inc. Primary endpoint: Emax response to capsaicin inhalation. Started Mar 2015; status: completed.
02
Drugs
gefapixant
03
Conditions
chronic cough
Beyond the preview
Go deeper on 2015-000464-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000464-34.